ZAI LAB LIMITED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.1 EUR | +1.26% |
|
-7.02% | -34.84% |
| 06-27 | Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing | MT |
| 06-20 | Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme | MT |
| Sales 2024 * | 393M 365M 537M | Sales 2025 * | 597M 554M 815M | Capitalization | 1.72B 1.6B 2.35B |
|---|---|---|---|---|---|
| Net income 2024 * | -270M -251M -369M | Net income 2025 * | -157M -146M -215M | EV / Sales 2024 * | 3.01 x |
| Net cash position 2024 * | 538M 500M 735M | Net cash position 2025 * | 275M 256M 376M | EV / Sales 2025 * | 2.42 x |
| P/E ratio 2024 * |
-6.53
x | P/E ratio 2025 * |
-11.3
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 9.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zai Lab Limited
More recommendations
More press releases
More news
| 1 week | -7.02% | ||
| Current month | -2.45% | ||
| 1 month | -5.92% | ||
| 3 months | +4.61% | ||
| 6 months | -33.75% | ||
| Current year | -34.84% |
1 week
15.90
17.10
1 month
15.9018.50
3 years
12.60146.00
5 years
12.60161.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ying Du
CEO | Chief Executive Officer | 59 | 14-03-31 |
Ya jing Chen
DFI | Director of Finance/CFO | 56 | 21-08-31 |
Joshua Smiley
PSD | President | 54 | 22-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Diekman
BRD | Director/Board Member | 81 | 16-12-31 |
Peter Wirth
BRD | Director/Board Member | 73 | 16-12-31 |
Lonnie Moulder
BRD | Director/Board Member | 66 | 18-12-31 |
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 16 | +0.63% |
| 24-07-02 | 15.9 | -0.62% |
| 24-07-01 | 16 | -1.84% |
| 24-06-28 | 16.3 | -1.81% |
| 24-06-27 | 16.6 | -2.92% |
Delayed Quote Börse Stuttgart, July 03, 2024 at 02:07 am
More quotes
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
Sector
Pharmaceuticals
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
17.37
USD
Average target price
50.79
USD
Spread / Average Target
+192.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.58% | 41.61B | |
| -11.57% | 33.32B | |
| +78.26% | 28.8B | |
| -14.73% | 15.61B | |
| -6.00% | 13.27B | |
| -12.55% | 11.46B | |
| +166.50% | 10.06B | |
| -54.80% | 9.09B | |
| +3.00% | 8.9B |
- Stock Market
- Equities
- ZLAB Stock
- 1ZL Stock
